Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Hank

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
Seminars in Oncology|February 1, 1990
In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapiesJ A Sosman, J A Hank, P M Sondel
Oncology (Williston Park, N.Y.)|August 1, 1987
Status and potential of interleukin-2 for the treatment of neoplastic diseaseP M Sondel, J A Hank, P C Kohler
Nature|September 27, 1979
Human T lymphocytes clones reactive in primed lymphocyte typing and cytotoxicityF H Bach, H Inouye, J A Hank, et al.
Cellular Immunology|December 1, 1987
Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAbB P Chen, M Malkovsky, J A Hank, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Activation of multiple effector mechanisms to enhance tumor immunotherapyJ A Hank, M R Albertini, J Schiller, et al.
Cellular Immunology|September 1, 1988
CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I moleculesB P Chen, R DeMars, J A Hank, et al.
Scandinavian Journal of Immunology|January 1, 1980
TCGF production for cloning and growth of functional human T lymphocytesH Inouye, J A Hank, B J Alter, et al.
Cellular Immunology|January 10, 1996
Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodiesS C Helfand, J A Hank, J Gan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
Proliferative responses to a nonspecific factor produced by irradiated stimulating cells can simulate antigen-specific secondary responses in the primed lymphocyte testP J Reitnauer, L R Brown, J A Hank, et al.
The Journal of Clinical Investigation|September 1, 1985
A human T cell clone that mediates the monocyte procoagulant response to specific sensitizing antigenB S Schwartz, P J Reitnauer, J A Hank, et al.
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Seminars in Oncology|February 1, 1990
In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapiesJ A Sosman, J A Hank, P M Sondel
Oncology (Williston Park, N.Y.)|August 1, 1987
Status and potential of interleukin-2 for the treatment of neoplastic diseaseP M Sondel, J A Hank, P C Kohler
Nature|September 27, 1979
Human T lymphocytes clones reactive in primed lymphocyte typing and cytotoxicityF H Bach, H Inouye, J A Hank, et al.
Cellular Immunology|December 1, 1987
Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAbB P Chen, M Malkovsky, J A Hank, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Activation of multiple effector mechanisms to enhance tumor immunotherapyJ A Hank, M R Albertini, J Schiller, et al.
Cellular Immunology|September 1, 1988
CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I moleculesB P Chen, R DeMars, J A Hank, et al.
Scandinavian Journal of Immunology|January 1, 1980
TCGF production for cloning and growth of functional human T lymphocytesH Inouye, J A Hank, B J Alter, et al.
Cellular Immunology|January 10, 1996
Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodiesS C Helfand, J A Hank, J Gan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
Proliferative responses to a nonspecific factor produced by irradiated stimulating cells can simulate antigen-specific secondary responses in the primed lymphocyte testP J Reitnauer, L R Brown, J A Hank, et al.
The Journal of Clinical Investigation|September 1, 1985
A human T cell clone that mediates the monocyte procoagulant response to specific sensitizing antigenB S Schwartz, P J Reitnauer, J A Hank, et al.
Pageof 10